| Title |
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, July 2012
|
| DOI | 10.1007/s00262-012-1319-0 |
| Pubmed ID | |
| Authors |
Surasak Phuphanich, Christopher J. Wheeler, Jeremy D. Rudnick, Mia Mazer, HongQian Wang, Miriam A. Nuño, Jaime E. Richardson, Xuemo Fan, Jianfei Ji, Ray M. Chu, James G. Bender, Elma S. Hawkins, Chirag G. Patil, Keith L. Black, John S. Yu |
| Abstract |
This study evaluated the safety and immune responses to an autologous dendritic cell vaccine pulsed with class I peptides from tumor-associated antigens (TAA) expressed on gliomas and overexpressed in their cancer stem cell population (ICT-107). |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 25% |
| Peru | 1 | 13% |
| Spain | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
| Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 283 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 2% |
| Switzerland | 2 | <1% |
| Netherlands | 2 | <1% |
| Brazil | 1 | <1% |
| Germany | 1 | <1% |
| Spain | 1 | <1% |
| India | 1 | <1% |
| Unknown | 270 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 52 | 18% |
| Researcher | 52 | 18% |
| Student > Bachelor | 34 | 12% |
| Student > Master | 28 | 10% |
| Other | 19 | 7% |
| Other | 52 | 18% |
| Unknown | 46 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 80 | 28% |
| Agricultural and Biological Sciences | 54 | 19% |
| Immunology and Microbiology | 25 | 9% |
| Biochemistry, Genetics and Molecular Biology | 23 | 8% |
| Neuroscience | 16 | 6% |
| Other | 26 | 9% |
| Unknown | 59 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2023.
All research outputs
#2,475,531
of 24,929,945 outputs
Outputs from Cancer Immunology, Immunotherapy
#115
of 2,950 outputs
Outputs of similar age
#15,259
of 169,392 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#1
of 33 outputs
Altmetric has tracked 24,929,945 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,950 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,392 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.